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Abstract
Background: Although cervical cancer is preventable, most women in sub-Saharan Africa (SSA) do not receive
routine screening and few treatment options exist. Female Sex Workers (FSWs) are among the Ugandan female
population at highest risk of acquiring sexually transmitted infections (STIs) including HIV and human papilloma
viruses (HPV), the cause of cervical cancer. We report one-year experiences of visual inspection with acetic acid (VIA)
positivity among FSWs in the early detection of pre-cancerous and cancerous cervical lesions in Kampala, Uganda.
Methods: Between June 2014 and July 2015, we enrolled FSWs into a cross-sectional study at a research clinic. The
women were screened using the VIA method (application of 3–5 % acetic acid to the cervix). All VIA positive
women were referred to a tertiary hospital for colposcopy, biopsy, and immediate treatment (if indicated) at the
same visit according to national guidelines. Data on socio-demographic, sexual behaviour, sexual reproductive
health and clinical characteristics were collected. We used logistic regression to identify factors associated with VIA
positivity.
Results: Of 842 women assessed for eligibility, 719 (85 %) of median age 30 (IQR 26, 35) were screened, and 40
(6 %) women were VIA positive. Of the 24 histology specimens analysed, 6 showed inflammation, only 1 showed
cervical intraepithelial neoplasia (CIN) 1, 13 women showed CIN2/3, while 4 women already had invasive cervical
cancer. The overall prevalence of HIV was 43 %, of whom only 35 % were receiving ART. In the age-adjusted
analysis, VIA positivity was more likely among women who reported having > 100 life-time partners (aOR = 3.34,
95 %CI: 1.38–8.12), and HIV positive women (aOR = 4.55; 95 %CI: 2.12–9.84).
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Conclusions: We found a relatively low proportion of VIA positivity in this population. The experience from our
program implies that the VIA results are poorly reproducible even among a category of trained professional health
workers. VIA positivity was more likely among women with a high number of sexual partners and HIV infection.
Interventions for improving cervical cancer screening should be recommended as part of HIV care for FSWs to
reduce the disease burden in this population.
Keywords: Female sex workers (FSWs), visual inspection with acetic acid (VIA), cervical intra-epithelial neoplasia
(CIN), screening, HIV
Background
Cervical cancer continues to be a major public health
problem worldwide [1]. Globally, cervical cancer is the
fourth most common cancer among women, with more
than 500,000 new cases occurring annually [2, 3]. More
than 85 % of the women who die of cervical cancer an-
nually live in low- and middle-income countries
(LMICs) with sub-Saharan Africa (SSA) carrying the
highest burden[4]. In Uganda, studies have shown an
overall trend of elevated cervical cancer incidence, with
over 80 % of women diagnosed with advanced disease
[5, 6]. Cervical cancer is a preventable disease if precan-
cerous lesions are detected early through effective
screening programs. World Health Organization
(WHO) recommends visual inspection with acetic acid
(VIA) as the primary approach for cervical screening in
resource-constrained settings [2]. In principle, this
screening method is a less complex technique and can
be performed by trained healthcare providers with
different backgrounds e.g. doctors, and nurses [7].
Compared to women in the general population, female
sex workers (FSWs) are among the Ugandan female
populations at the highest risk of acquiring sexually
transmitted infections (STIs) including HIV and human
papilloma viruses (HPV), the cause of cervical cancer
[8]. Earlier reports show that high risk sexual behaviour
and HIV infection are associated with an increased risk
of HPV infection among FSWs [9]. Published data also
indicates that Cervical Intraepithelial Neoplasia (CIN),
and invasive cervical cancer are more common in high-
risk women compared to their counterparts [10]. WHO
recommends that high-risk women including FSWs
should be screened more often than other women in the
general population [2]. However, due to a range of
social-cultural challenges including stigma and discrim-
ination, FSWs are usually hard to reach and do not re-
ceive regular cervical screening services [11].
Although VIA is the standard of care in many LMICs,
the diagnostic accuracy in detecting precancerous and
invasive cancerous cervical lesions varies across studies
[12]. For example in a meta-analysis on the accuracy of
VIA in LMICs, healthcare providers correctly identified
between 41 and 92 % of women with cervical
intraepithelial neoplasia (CIN) grade 2 or worse [13].
The reference standard test (or gold standard) that was
selected for this review was either a combination of col-
poscopy and histology, or histology without colposcopy
[13]. These data suggest that the VIA method has some
limitations. According to previous authors, the import-
ant causes of variations could be due to highly subjective
results dependent on individual interpretation, quality
assurance and training, the variation of light source, the
procedure for 3–5 % acetic acid preparation, and its
storage [14]. Thus, acquiring good VIA skills is
mandatory to lower the impact of these limitations.
However, the health providers’ VIA screening skills
have been shown to improve significantly over time with
continuous exposure and practice [15]. For example in
Ghana, the health care providers who had been trained
up to seven years with regular supervision maintained
high visual inspection performance [16]. In Uganda, the
Ministry of Health (MoH) Non-Communicable Diseases
(NCDs) division has developed comprehensive national
cervical cancer prevention and control guidelines [17] to
strengthen the capacity of health-care providers in their
health care settings. Continuous experience, availability
of standardized protocols, quality checks, and routine
supervision are crucial for improving VIA accuracy.
Although scaling up of VIA-based programs into na-
tional programs is already taking place in many SSA
countries [7], data on the evaluation of service delivery
among high-risk women including FSWs is still scarce.
Understanding the implementation of VIA screening
programs among FSWs is an essential step in developing
effective interventions for the prevention and control of
cervical cancer in this population [18, 19].
Methods
Aim, design and setting
We conducted a cross-sectional study between June
2014 and July 2015 to investigate VIA positivity among
FSWs in the early detection of pre-cancerous and can-
cerous cervical lesions at the Good Health for Women
Project (GHWP) clinic in Kampala, Uganda. The clinic
was established in 2008 to study HIV and STIs epidemi-
ology and to implement HIV/STIs prevention among
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FSWs. The clinic, a stand-alone clinic located in a peri-
urban suburb in Southern Kampala, the capital city of
Uganda reported a high HIV/STIs prevalence combined
with high-risk behaviour in 2011 [8]. The clinic offers
HIV care and preventative services, sexual and repro-
ductive health (SRH) services such as syndromic man-
agement of STIs, family planning, antenatal care,
promotion and distribution of free condoms, and risk re-
duction counselling to both HIV positive and negative
FSWs.
Participants
The participants were asymptomatic, healthy and previ-
ously unscreened FSWs who were receiving targeted
HIV prevention, care, and treatment services at a dedi-
cated GHWP clinic. FSWs were defined as women hav-
ing sex with men in exchange for money, favours or
other goods either regularly or casually at least once in
the past 12 months.
Eligibility criteria
The eligibility criteria for participation in the study in-
cluded: (1) being a FSW aged ≥ 14 years old; (2) a resi-
dent of the catchment area; (3) no previous history of
total hysterectomy; (4) not using any intra-vaginal medi-
cation at the time of the study visit; (5) ability to provide
informed consent; (6) had not been previously diagnosed
with cervical cancer.
We excluded those; (1) who were very ill requiring
emergency care; (2) women with evidence of acute STIs;
(3) women less than 12 weeks after delivery; (4) pregnant
women; (5) currently menstruating; and (6) women with
known allergy to acetic acid. For women who were men-
struating, the screening procedure was deferred until
menstruation was over.
VIA program and procedures
a) VIA training and quality assurance
Before implementation of the VIA program, the nurses
and clinicians were given a 5-days training using the
WHO guidelines [20]. The training included a mixture
of interactive and practical sessions and discussions. The
facilitators included a senior gynaecologist and midwife
from St Francis hospital Nsambya, a tertiary referral hos-
pital. Following hands-on experience under supervision
for two consecutive weeks, the trained staff were allowed
to screen the women independently. Periodic reorienta-
tion sessions and routine quality checks were conducted
to improve quality assurance. The VIA screening proto-
col was distributed in the clinic to use during the screen-
ing of the women. Awareness campaigns among the
FSWs were performed by the trained staff during the
health education activities at the GHWP clinic.
Information, education and communication (IEC) mate-
rials were used to assist in this process.
b) Recruitment and VIA screening procedure
The women were recruited during their three-monthly
routine clinic visits. Those who were interested and eli-
gible for screening were offered the screening test after
obtaining informed consent. VIA was performed accord-
ing to the Uganda MoH guidelines [17]. The women
underwent a routine vaginal examination using a sterile
bivalve self-retaining vaginal speculum. The squamo-
columnar junction (SCJ) was identified and any secre-
tions or exudate were cleaned off before applying a cot-
ton swab soaked in a 3–5 % freshly prepared acetic acid
solution to the cervix. The results were recorded after
1–3 min using a bright halogen lamp. The VIA result
was classified as negative, positive or inconclusive. Pre-
cancerous and cancerous lesions were recorded positive
when a well-defined, dense aceto-white area with regular
margins appeared attached to the SCJ or if the whole
cervix or cervical growth turned white. The test was re-
ported negative if no change was observed or suspicious
for invasive cancer, i.e., if no growth or ulcerative lesion
was observed [21]. If there was any uncertainty about
the lesion observed, such women were recalled for
rescreening. All VIA positive women were immediately
informed and offered accompanied referral to the senior
gynaecologist at St Francis hospital Nsambya for colpos-
copy, and further management. The participants had a
pregnancy test followed by a general physical and gynae-
cological exam. The entire screening procedure and pro-
cedures done at referral facility were paid for by project
to ensure that all women who tested positive receive
treatment.
c) Clinical management procedure
The women with a positive VIA result were referred
to a collaborating tertiary hospital on the same day
for further evaluation in accordance with the “screen
and treat” program [17]. At the referral facility, col-
poscopy was done to grade the lesions and biopsies
taken from areas which looked to be suspicious or
abnormal. Colposcopic findings were reported as
normal, inflammation, probable low- or high-grade
precancerous lesions, or suspected invasive cancer.
The colposcopic findings and procedure were ex-
plained to the woman. Immediate treatment with
cryotherapy was offered in the same session, if the
lesion involved < 75 % of the transformational zone,
did not involve the endocervix or if there was no
evidence of invasive cancer. Women with lesions in-
volving > 75 % of the transformation zone, endocervi-
cal involvement or suspicious of invasive cancer
were offered loop electrosurgical excision procedure
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(LEEP) to remove abnormal cervical tissues [22].
Similarly, those who were found to have invasive
cervical cancer were managed as per the national
guidelines [17]. All the women who were treated
were given a course of antibiotics for a week. Cer-
vical biopsy specimens were analyzed and the results
were reported using the CIN system [23] and ex-
plained to the participant during the follow-up clinic
visit 1–4 weeks later.
If any STIs were diagnosed, the women were offered
free treatment using a syndromic approach at the
GHWP clinic. The women who tested HIV positive were
enrolled into care. Pregnant women were provided with
iron and folate supplements according to Uganda na-
tional clinical guidelines [24]. The women were also en-
couraged to invite their male regular partners (MRPs) to
the clinic for free HIV/STIs screening and treatment as
well as counselling on safe medical male circumcision
and condom use. The details of all the medical proce-
dures remained totally confidential.
Laboratory procedures
As part of routine clinical care, blood samples were col-
lected by an experienced and trained health worker for
assessing HIV sero-positivity at the GHWP clinic labora-
tory.Participants received confidential HIV pre-test and
post-test counselling on the study visit. HIV status was
determined by performing a rapid HIV test (Determine,
Statpak, Unigold) on a serum sample according to the
Uganda National algorithms [25] for HIV testing HIV
status was recorded as negative or positive. The HIV test
results were linked to participants by their unique study
identification number. Samples of urine were taken off
for routine testing for the presence of Human Chorionic
Gonadotropic (hCG) at the GHWP clinic laboratory.
The biopsy cervical specimens were analysed at the re-
ferral hospital laboratory. The 3–5 % acetic acid was
freshly prepared at the GHWP clinic laboratory by care-
fully adding 5 mL of glacial acetic acid into 95 mL of
distilled water and mixing thoroughly. Unused acetic
acid was discarded at the end of the day.
Data collection and study measures
After obtaining written informed consent, eligible
FSWs were consecutively enrolled and face-to-face
semi-structured interviews conducted. Counsellors
collected data on socio-demographic characteristics,
sexual behaviour and clinical characteristics. The pri-
mary outcome of this study was VIA positivity which
was categorised as negative or positive. Socio-
demographic measures included age, marital status,
education level, alcohol use, and illicit drug use. Alco-
hol use was assessed by using a standardized WHO
Alcohol Use Disorders Identification Test (AUDIT)
[26]. Alcohol use was classified into three categories
i.e. harmless or low-risk drinkers: score 1–7, harmful
or high-risk drinkers: score 8–19 and alcohol
dependent: score 20+. The sexual behaviour charac-
teristics included: the total number of lifetime part-
ners, condom use at last sexual intercourse, and age
at first sexual intercourse. Sexual and reproductive
health characteristics included: age at first pregnancy,
parity, family planning use in the last 12 months, and
family planning method. Participants’ clinical charac-
teristics included; the presence of STI symptoms in
the last 12 months, HIV status, receiving ART, VIA
result, and Biopsy result. Presence of STI symptoms
was determined if a FSW self-reported having had
any symptoms suggesting STIs in the last 12 months
including vaginal discharge, genital ulcer, and pain.
HIV status was categorised as negative or positive.
The histopathological findings were categorized into
five categories: normal, inflammation, CIN 1 (low-
grade cervical lesions), CIN 2/3 (high-grade cervical
lesions), and invasive cervical cancer.
Statistical analysis
Data were double entered in Microsoft Access, cleaned,
and exported to STATA 14.0 (StataCorp, College Sta-
tion, TX, USA) for analysis. We resolved discrepancies
by checking the source documents for clarification. Cat-
egorical demographic and clinical characteristics were
summarized by counts and percentages. Continuous var-
iables were summarized by means and standard devia-
tions or medians and interquartile ranges. The
proportion of those who were VIA positive was analysed
by the different demographic, sexual behavioural and
clinical characteristics. Factors for which the association
attained statistical significance on log likelihood ratio
test (LRT) of p < 0.20 were selected for the multivariable
logistic regression model. Logistic regression models
were fitted to identify factors associated with VIA posi-
tivity at unadjusted analysis. Factors were retained in the
final multivariable logistics regression model if their in-
clusion did not make the fit of the model significantly
worse at the 5 % level on a likelihood ratio test (LRT).
Results
Recruitment profile
During the study period, 842 women were screened to
participate at GHWP clinic (Fig. 1), of these, 123 (15 %)
were excluded: 51 (6 %) were ineligible; (pregnant [n =
15], not FSWs [n = 7], evidence of acute STIs [n = 20],
and < 12 weeks after delivery [n = 9]); 72 (9 %) were not
analysed; (missed appointments [n = 45], and insufficient
data on study independent variables [n = 27]). Thus, a
total of 719 FSWs were included in the analysis (Fig. 1).
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Participants’ characteristics
Seven hundred and nineteen women were included in
the analysis. Their median age was 30 years (IQR, 26–
35). More than half (54 %) of the FSWs were aged 25–34
years, more than half (56 %) attained at least primary
education and above, and about two thirds (64 %) were
divorced/separated. About a third had ever smoked, and
12 % reported being alcohol dependent. 43 % reported to
have had at least 50 lifetime sexual partners, and about
half (52 %) reported using condoms during the last sex-
ual intercourse.
More than half (55 %) reported their first sexual inter-
course between the age of 15–19 years and the median
age 16 years (IQR, 15–18). Regarding age at first preg-
nancy, the median was 17 years (IQR, 16–19) and more
than half (55 %) had their first pregnancy at < 18 years.
More than 40 % had 1–2 children, nearly two thirds
(58 %) were using family planning in the past 12 months,
with the injectable contraceptive being the most pre-
ferred method (25 %). Most (71 %) reported not having
signs and symptoms of STIs in the last three months.
HIV prevalence was 43.8 %, out of whom only 35 % were
receiving ART. Overall VIA positivity was 6 % (40/719).
Of the 24 histology cervical specimens analysed, 6
women showed normal or inflammation, only 1 showed
CIN1, about half [13] of the women showed CIN2/3,
while 4 women already had invasive cervical cancer.
(Table 1).
Colposcopic findings and management of VIA positive
FSWs at the referral hospital
From the 40 VIA positive women, 26 (65 %) were re-
ferred for colposcopy and 14 (35 %) were lost to follow
up (LTFUP). Of the 26 colposcopic assessments done, 2
women had inflammation, 13 had low-grade precancer-
ous lesions, 7 had high-grade lesions, while 4 had sus-
pected invasive cancer. Of the 14 women who had
CIN2/3 & CIN 1 from the biopsy results, 11 accepted
immediate treatment (cryotherapy, 8; LEEP,3). The 4
women with invasive cervical cancer also complied with
the treatment. The remaining 3 refused treatment.
(Fig. 2).
VIA positivity and associated factors
At unadjusted analysis, VIA positivity more likely among
HIV positive women (uOR = 4.42; 95 %CI: 2.13–9.14). In
age-adjusted analysis, VIA positivity was less likely
among women aged 14–24 years old (uOR = 0.18;
95 %CI: 0.04–0.81), and was more likely women who re-
ported having > 100 lifetime partners (aOR = 3.34,
95 %CI: 1.38–8.12), and HIV positive women (aOR =
4.55; 95 %CI: 2.12–9.84). (Table 2).
Fig. 1 Recruitment profile of FSWs for VIA screening at Good Health for Women Project (GHWP) clinic in Kampala, Uganda (2014–2015)
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Discussion
This study reports one-year experiences of VIA-based cer-
vical screening among asymptomatic, apparently healthy
and previously unscreened Ugandan FSWs. Our experi-
ence has shown that the proportion of VIA positivity was
surprisingly low in this high-risk population. Similar dis-
crepancies were also reported in the Nigerian and
Table 1 Characteristics of FSWs who were screened for pre-
cancerous and cancerous lesions using VIA at Good Health for
Women Project (GHWP) clinic in Kampala, Uganda (2014–2015
Socio-demographic characteristics
Characteristic Frequency Percentage (col % )
Age, years (N = 717)
Median, 30 (IQR, 26–35)
18–24 138 19
25–34 386 54
≥ 35 193 27
Education level ((N = 687)
Less than primary 303 44
Primary or greater 384 56




Never married 106 15
Smoker (N = 719)
Never 501 70
Ever 218 30
Alcohol use (N = 651)
Low risk 320 49
Harmful/high risk 251 39
Alcohol dependent 80 12
Sexual behaviour characteristics
Total number of lifetime partners (N = 707)
≤ 50 305 43
51–100 268 38
> 100 or cannot remember 134 19
Condom use at the last sexual intercourse (N = 634)
No 306 48
Yes 328 52
Age at first sexual intercourse, years (N = 712)
Median; 16 (IQR: 15, 18)
< 15 266 37
15–19 391 55
> 20 55 8
Sexual and reproductive health characteristics
Age at first pregnancy, years (N = 671)
Median; 17 ( IQR, 16–19)
< 18 369 55
18+ 302 45
Table 1 Characteristics of FSWs who were screened for pre-
cancerous and cancerous lesions using VIA at Good Health for
Women Project (GHWP) clinic in Kampala, Uganda (2014–2015
(Continued)
Socio-demographic characteristics
Characteristic Frequency Percentage (col % )





Family planning use in the last 12 months (N = 719)
Yes 420 58
No 299 42
Family planning method (N = 719)
None 299 42
Condoms 139 19
Injectable contraceptive 176 25
Oral contraceptive 45 6
Implants (progesterone) 23 3
Other method 37 5
Participants’ clinical characteristics




HIV status (N = 719)
Positive 315 44
Negative 404 56
Receiving ART (N = 719)
Yes 252 35
No 467 65
VIA result (N = 719)
Negative 679 94
Positive 40 6
Biopsy result (N = 24)
Normal or Inflammation 6 31
Low grade lesions (CIN I) 1 4
High grade lesions (CIN II-III) 13 50
Invasive cancer 4 15
Namale et al. Infectious Agents and Cancer           (2021) 16:31 Page 6 of 11
Malawian studies [27, 28]. In contrast, a higher prevalence
of VIA positivity was observed among South African
FSWs [18]. According to previous reports, these variations
could be due to the health provider’s skills and experience
in the interpretation of the VIA result [14]. In this study,
the most likely explanation is that, although our midwives
and clinicians were trained, it’s possible that not all of
them attained the same level of skill. Also, the VIA test
was a new service at the GHWP clinic and our health
workers did not have previous experience. We believe that
perhaps with more practice and experience, their visual
inspection accuracy would improve. This study provides a
Table 2 Characteristics of FSWs and association with VIA positivity in Kampala, Uganda
Characteristic N # VIA positive
(col%)
Unadjusted OR (95 %CI) Age-adjusted OR (95 %CI) Fully adjusted OR
(95 %CI)
Current marital status (N = 713)
Married/cohabiting 109 3 (2.8) 0.73 (0.17–3.18) 0.64 (0.15–2.75) 0.52 (0.10–2.58)
Widowed 40 4 (10.0) 2.65 (0.70–10.09) 2.20 (0.58–8.24) 1.74 (0.39–7.77)
Separated/divorced 458 29 (6.3) 1.67 (0.60–4.67) 1.33 (0.48–3.70) 2.25 (0.36–4.06)
Single 106 4 (3.8) 1.0 1.0 1.0
Smoker (N = 719)
Never 501 26 (5.2) 1.0 1.0 1.0
Ever 218 14 (6.4) 1.20 (0.66–2.32) 1.21 (0.65–2.27) 1.12 (0.59–2.14)
Alcohol use pattern following AUDIT score (N = 651)
Harmless or low-risk drinkers 320 21 (6.6) 1.31 (0.46–3.72) 1.11 (0.40–3.11) 1.21 (0.42–3.50)
Harmful or high-risk drinkers 251 14 (5.6) 1.11 (0.38–3.30) 1.04 (0.36–3.03) 1.11 (0.38–3.30)
Alcohol-dependent 80 4 (5.0) 1.0 1.0 1.0
Number of lifetime partners (N = 707)
≤ 50 305 15 (4.9) 1.0 1.0 1.0
51–100 268 10 (3.7) 0.75 (0.35–1.66) 0.74 (0.34–1.64) 1.07 (0.40–2.86)
> 100 134 12 (9.0) 1.82 (0.88–3.78) 1.69 (0.81–3.52) 3.34 (1.38–8.12)
Number sexual partners in last month (N= 594)
< 5 234 14 (6.0) 1.0 1.0 1.0
5–19 137 6 (4.4) 0.73 (0.29–1.86) 0.82 (0.32–2.07) 0.63 (0.23–1.64)
20–49 88 3 (3.4) 0.57 (0.17–1.94) 0.67 (0.20–2.29) 0.53 (0.16–1.84)
50+ 135 7 (5.2) 0.87 (0.36–2.09) 0.98 (0.41–2.36) 0.58 (0.23–1.54)
Condom use in the last 3 months (N = 634)
Inconsistent use 306 21 (6.9) 1.0 1.0 1.0
Consistent use 328 17 (5.2) 0.75 (0.41–1.40) 0.80 (0.43–1.48) 1.05 (0 0.51–2.17)
Age at first sex (N = 712)
< 15 266 16 (6.0) 1.0 1.0 1.0
15–19 391 22 (5.6) 0.94 (0.50–1.75) 0.94 (0.50–1.74) 0.89 (0 0.45 -1.78)
> 20 55 1 (1.8) 0.30 (0.04–2.23) 0.36 (0.04–2.64) 0.30 (0 0.04 -2.29)
Age at first pregnancy (N = 671)
< 18 369 17 (4.6) 1.0 1.0 1.0
18+ 302 20 (6.6) 1.44 (0.77–2.69) 1.49 (0.80–2.77) 1.49 (0 0.76–2.91)
HIV status (N = 719)
Negative 404 31 (7.7) 1.0 1.0 1.0
Positive 315 9 (2.9) 4.42 (2.13–9.14) 3.90 (1.37–11.09) 4.55 (2.12–9.84)
Signs and symptoms of STIs (N = 719)
No 512 28 (5.5) 1.0 1.0 1,0
Yes 207 12 (5.8) 1.06 (0.55–2.04) 1.00 (0.51–1.97) 1.06 (0.55–2.02)
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possible example of difficulties in interpreting VIA results
even when VIA is used in the best possible circumstances.
Additionally, the low VIA positivity in this study could
also have arisen from the fact that our nurses were more
likely to label unclear visual inspection findings as nega-
tive, in order not to miss cases of inflammation and STIs
given that these were FSWs at high risk of infection.
Thus, lesions classified as inflammation may have been
low-grade precancerous lesions, resulting in higher false-
negative rates and a subsequent low VIA positivity rate.
Although different study populations have reported high
proportions of VIA positivity [18, 29], the findings in the
present study reveal that cervical cancer is still a signifi-
cant public health problem in this population. This calls
for routine screening service provision given that early
detection and treatment is more cost-effective than
treating advanced disease [30].
Interestingly, in this study, a high proportion of VIA
positive women were considered positive after a colpo-
scopic examination. The rate of colposcopic positivity in
this study was higher than what was reported in Côte
d’Ivoire [31]. This high achievement in performance is
relevant for scaling up cervical cancer screening and
treatment programmes using VIA even at lower-level fa-
cilities. Hence, our results indicate that visual screening
tests are promising methods for the early detection of
pre-cancerous and cervical cancerous lesions in key pop-
ulations. The apparent subjectivity of VIA as a method
can be overcome with the high-quality, competency-
based training and quality assurance approach used in
many studies [32, 33].
We also report a high burden of cervical dysplasia
among these previously unscreened high-risk women.
Our histology results show that almost half of the
referred women had CIN2/3. The CIN2/3 histology
results in our study were higher than those reported
earlier [29]. It is possible that a large percentage of
FSWs were infected with high-risk HPV. FSWs con-
stitute a very high-risk group for HIV as well as
HPV infections [34]. Across SSA, the pre-cancerous
and invasive cervical cancer disease burden among
high-risk women is substantial [19, 34]. However,
even though our FSWs regularly received vaginal ex-
aminations at GHWP clinic, the data gathered in
this study calls for the need to perform regular cer-
vical cancer screening in this population.
With regard to factors associated with VIA positivity,
our results show that it was more likely among HIV
positive women and those with multiple sexual partners.
This is consistent with earlier epidemiological reports
among FSWs [19, 35]. However, this is not particularly
surprising because HIV is a known risk factor for in-
creased VIA positivity and is common among FSWs
worldwide [19, 29]. It may be argued that, since HIV
and HPV are both STIs, sharing common modes of
transmission, women engaging in riskier sexual practices
and behaviours may have a greater likelihood of having
HIV and/or STIs infected partners leading to greater ex-
posure to both viruses. In countries with high HIV
prevalence like Uganda [36], the integration of cervical
cancer screening into routine HIV care provides an ideal
platform to reach HIV positive women.
Fig. 2 The flow of the referred VIA positive FSWs at the referral tertiary hospital in Kampala, Uganda (2014–2015)
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Implications for policy and clinical practice
These results have important implications for efficient
service delivery of cervical screening programs among
FSWs. The VIA test was mostly performed by trained
nurses who are the main providers of these services
throughout SSA. However, given the heterogeneity of re-
sults across studies and the relatively low rates in ours,
we are clearly underestimating the true burden of dis-
ease. This means that VIA, in our hands had low sensi-
tivity. More broadly, it is not a very reproducible test.
That said, we found some (but certainly not all) cases
and linked them effectively into care. This same day
linkage of the VIA screen-positives to the diagnosis and
treatment facility was critical for the successful imple-
mentation of our program. Our study, therefore, pro-
vides important information about the feasibility of the
“screen and treat” strategy for preventing cervical cancer,
which has been recommended by the WHO for low-
resource countries [2]. In Uganda, the “screen and treat”
strategy has been advocated [17, 37], but these services
may not be available in most facilities especially at pri-
mary health care level. In the context of FSWs, it is even
more important to screen and treat on the same day
given that this is a highly mobile population [38, 39].
Cervical cancer screening and treatment of CIN using
“screen and treat” strategy needs to be integrated into
targeted interventions that are ongoing for HIV preven-
tion, care and support for FSWs. Based on our findings,
there is a need to have networks and collaborations
among FSW-led organisations to set up acceptable and
accessible health services that integrate cervical cancer
screening and HIV/STIs care.
Our study had some strengths and limitations. First,
this being our first VIA screening experience we did not
have a systematic reference test to confirm whether VIA
positive or negative tests were correct. However, import-
antly, VIA remains highly related to the health worker
skills, subjective nature of decision and is subject to mis-
classification bias, leading to possible under or over
identification of cervical lesions [12]. Secondly, because
we used a syndromic approach to manage STIs in our
clinic due to financial limitations, there was no system-
atic detection of STIs as co-factors/confounders in the
laboratory. Additionally, we did not investigate the
prevalence of HPV and its subtypes to correlate HPV
and VIA also due to financial limitations. Thirdly, for all
the women who were referred for a colposcopic proced-
ure, some were lost to follow up. Therefore, the informa-
tion on VIA positive women that were referred for
colposcopy is not sufficient to adequately determine the
real picture of cervical lesions in this population. Im-
portantly, a high proportion of VIA positive women
were considered positive after a colposcopic examin-
ation. This high rate of CIN2/3 detection shows that
VIA had reasonably high HPV detection rates. Lastly,
since this was a single-site study, the results might not
be generalizable to other key population clinics in
Kampala. However, despite all these challenges, we be-
lieve that our experiences presented here can be useful
to other key population settings in the country. The re-
sults achieved and lessons learned can serve as a guide
for other low-resource countries. Also, the findings in
this study add to the existing knowledge of cervical can-
cer screening interventions among key populations in
sub-Saharan Africa.
Conclusions
The proportion of VIA positivity that we identified was
comparatively low in this population compared with
studies from elsewhere in sub-Saharan Africa. The ex-
perience from our program implies that the VIA results
are poorly reproducible even among a category of
trained professional health workers. Our findings also
suggest the need for systems to ensure quality assurance
which is critical for health provider performance on cer-
vical screening. VIA positivity was associated with a high
number of sexual partners and HIV infection. Interven-
tions aimed at improving cervical cancer screening
should be recommended as part of HIV care for FSWs
to reduce the preventable cervical cancer burden and as-
sociated mortality in this population.
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